Directed therapy for fungal infections: Focus on aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2431-2434

  Barnes, Rosemary A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antigens; Diagnostic driven; PCR; Pre emptive

Indexed keywords

ANTIFUNGAL AGENT; BIOLOGICAL MARKER; GALACTOMANNAN;

ARTICLE; ASPERGILLUS; ENZYME IMMUNOASSAY; FUNGUS HYPHAE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ANTIGENS; DIAGNOSTIC DRIVEN; PCR; PRE-EMPTIVE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG RESISTANCE, FUNGAL; DRUG UTILIZATION; HUMANS;

EID: 84886302192     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt227     Document Type: Article

References (28)

1. Oeser C, Lamagni T, Heath PT et al. The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009. Pediatr Infect Dis J 2013; 32: 23-6.
2. Hahn-Ast C, Glasmacher A, Mueckter S et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010; 65: 761-8.
3. Harrison D, Muskett H, Harvey S et al. Developmentand validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study. Health Technol Assess 2013; 17: 1-156.
4. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-70.
5. Agrawal S, Hope W, Sinko J et al. Optimizing management of invasive mould diseases. J Antimicrob Chemother 2011; 66 Suppl 1: i45-53.
6. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-27.
7. D'Haese J, Theunissen K, Vermeulen E et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50: 1258-63.
8. Karageorgopoulos DE, Vouloumanou EK, Ntziora Fet al. β-D-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52: 750-70.
9. Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008; 15: 1095-105.
10. Wiederhold NP, Najvar LK, Bocanegra R et al. Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis. J Clin Microbiol 2013; 51: 459-65.
11. Mengoli C, Cruciani M, Barnes RAet al. UseofPCRfor diagnosis of invasive aspergillosis: systematic reviewand meta-analysis. Lancet Infect Dis 2009; 9: 89-96.
12. White PL, Bretagne S, Klingspor Let al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48: 1231-40.
13. White PL, Mengoli C, Bretagne S et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol 2011; 49: 3842-8.
14. White PL, Perry MD, Loeffler J et al. Critical stages of extractingDNAfrom Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol 2010; 48: 3753-5.
15. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
16. Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2009; 29: 667-74.
17. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
18. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
19. Pagano L, CairaM, NosariAet al. The use and efficacyof empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 2011; 96: 1366-70.
20. Dignan FL, Evans SO, Ethell ME et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009; 44: 51-6.
21. Hebart H, Loffler J, Reitze H et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 2000; 111: 635-40.
22. Barnes RA, White PL, Bygrave C et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62: 64-9.
23. Barnes RA, Stocking K, Bowden S et al. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. J Infect 2013; doi:10.1016/j.jinf.2013.04.020.
24. Springer J, Morton CO, Perry M et al. Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol 2013; 51: 1445-50.
25. White PL, Parr C, Thornton C et al. An evaluation of real-time PCR, galactomannan ELISA and a novel lateral-flow device for the diagnosis of invasive aspergillosis. J Clin Microbiol 2013; 51: 1510-6.
26. Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematologica 2012; 97: 325-7.
27. Marchetti O, Lamoth F, Mikulska M et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-54.
28. Pagano L, Caira M, Cuenca-Estrella M. The management of febrile neutropenia in the posaconazole era: a new challenge? Haematologica 2012; 97: 963-5.